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2SUMMARY
It is established that preconditioning protects the myocardium against ischaemic injury 
(cell necrosis), and severe ventricular arrhythmias that occur during a subsequent ischaemia / 
reperfusion insult. Apart from the ’classical’ ischaemic preconditioning stimulus (i.e. brief 
coronary artery occlusions), cardiac pacing and physical exercise are also providing 
preconditioning-like cardioprotection. However, the effect of preconditioning on myocardial 
contractile function during ischaemia / reperfusion is less characterised.
Therefore, we aimed to examine in an anaesthetized open-chest canine model (1) the 
changes in regional myocardial contractility during repeated partial coronary artery occlusions 
and reperfusions, (2) the effects of cardiac pacing and physical exercise, as preconditioning 
stimuli, on functional changes, occurring during these low-flow ischaemia / reperfiision 
sequences 24 hours later; and (3) the possible involvement of nitric oxide (NO) in these 
occlusion / reperfusion-induced contractile changes. This was investigated by the 
intracoronary administration of L-NAME, a non-selective inhibitor of NO synthase enzymes.
We showed, that repeated low-flow ischaemia / reperfusion cycles (four times for 20 
min), produced by an approx. 50% reduction in resting blood flow of the left anterior 
descending (LAD) coronary artery, resulted in a progressive decrease in segmental shortening 
within the ischaemic area; the most pronounced reduction in contractility occurred during the 
third ischaemic insult. In dogs, subjected to cardiac pacing or physical exercise, 24h prior to 
low-flow ischaemia / reperfusion cycles, the contractility within the ischaemic segment was 
maximally decreased even during the first ischaemic episode, and no further changes occurred 
during the subsequent ischaemic / reperfusion interventions.
We have also demonstrated that NO plays a role in this kind of functional (contractile 
and metabolic) adaptation, since administration of L-NAME abolished these adaptive 
changes. In the presence of L-NAME, both in the control and paced dogs, the marked 
decrease in segmental shortening disappeared during the consecutive ischaemic episodes. 
Further, in the presence of L-NAME the lactate production was significantly increased, 
indicating a deterioration in metabolic conditions during ischaemia.
Our results show that preconditioning provides protection to the heart during 
ischaemia by decreasing regional contractile function and thereby the metabolic demands of 
the myocardium, and that NO plays an important role in this adaptive response. We think that 
our observations, that physical exercise can induce such an adaptation in the myocardium 
during ischaemia may have clinical importance.
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71. INTRODUCTION
Ischaemic heart disease is still one of the most serious problems facing modem 
cardiology and remains one of the leading causes of death in the developed countries. Genetic 
factors certainly determine the development of this pathological state but the risk is undoubtly 
increased by other factors, such as smoking, cholesterol rich diet, psychical stress and a 
sedentary lifestyle. Once the disease has developed, the only possibility is treatment for the 
rest of life and prevention of further progression and complications; at present we are not 
aware of a drug or other medical methods which completely obviate this condition.
Myocardial ischaemia, described as an imbalance between energy demand and 
metabolic substrate supply (including oxygen) of the heart [1], occurs when coronary artery 
blood flow is partially or fully obstmcted. Ischaemia results in cellular hypoxia and this leads 
to the depletion of high energy stores (glycogen, ATP, phosphocreatine) and accumulation of 
potentially harmful anaerobic catabolites [2-4]. These may influence the function of 
contractile elements, and of several proteins as well as membrane ion channels, resulting in 
complete disturbance of cell homeostasis and, at least, in endangering cell integrity.
1.1. New ischaemic syndromes
Partial or complete occlusion of a main coronary artery results in immediate 
contraction abnormalities within the supplied area [5, 6]. If the occlusion is prolonged (more 
than 20-30 min), despite restoration of blood flow, the ischaemia and reperfiision-induced 
alterations become irreversible, and ultimately myocardial cell death may occur [7]. However, 
this definite conception of the consequences of ischaemia-reperfusion injury has become more 
complex in the last decades, when the concept of the „new ischaemic syndromes” has been 
introduced by Opie and his colleagues [8, 9]. They defined three different states of the 
ischaemic myocardium: myocardial stunning, hibernation, and ischaemic preconditioning. 
These phenomenons are of great clinical importance and led clinicians to further 
understanding of the underlying mechanisms during ischaemic challenges of the myocardium.
81.1.1. Myocardial stunning
The phenomenon of the „stunned” myocardium was first described by Braunwald and 
Kloner in 1982 [10]. They showed in experimental studies that after reperfusion of the 
ischaemic myocardium, contractility remains suppressed for a longer period (hours to days) 
even in the lack of necrosis, despite of complete restoration of myocardial blood flow 
[reviewed in 11 and 12]. Thus, the hallmark of this condition is the presence of a „flow- 
function mismatch” after successful coronary reperfusion, with normal coronary blood flow 
but abnormal myocardial contractile function.
Although the clinical diagnosis of myocardial stunning is rather difficult, there are two 
major clinical situations where it has emerging importance; (i) reperfusion therapy in acute 
myocardial infarction (thrombolysis and/or coronary angioplasty) and (ii) reperfusion 
following cardiac surgery or heart transplantation. In general, stunning does not imply a 
decision-making process, because the myocardium is already reperfused. However, there are 
some high-risk situations, where stunning can become dangerous and must be treated with the 
administration of positive inotropic drugs and/or mechanical assistance (i.e. intra-aortic 
balloon counterpulsation).
The key elements in the pathophysiology of stunning are supposed to be the release of 
oxygen-derived free radicals during reperfusion, damage of membranes and other intra- and 
extracellular structures, as well as calcium overload [9,11,12].
1.1.2. Myocardial hibernation
This phenomenon has been first recognized under clinical conditions. In 1985 
Rahimtoola observed that after successful coronary revascularisation of the ischaemic 
myocardium, the previous, chronically depressed myocardial contractile function returned to 
normal or near to normal level (in the lack of previous infarction) [9, 13, 14]. According to 
the traditional view, the extent of chronic contractile dysfunction would reflect the amount of 
infarcted tissue. This concept has been changed since in hibernation the preservation of 
viability is due to the decreasing contractile function rather than to the occurrence of necrosis.
In classical terms the hibernating myocardium is not ischaemic. The typical signs of 
ischaemia (e.g. lactate production, ATP depletion, creatine kinase leakage) are absent despite 
the permanent, severe reduction in coronary blood flow [15-17]. However, after several weeks 
to months a significant loss of contractile elements [18] and other intra- and extracellular
9alterations occur [19-21], which are thought to be partialy or completely reversible following 
revascularisation.
It has been suggested that the hibernating myocardium reduces its function to the 
extent that blood flow and biochemical function are again in equilibrium. Although there is 
evidence that segmental contractile function is decreased in proportion to the reduction in 
regional myocardial blood flow (i.e. „perfusion-contraction matching”; [22]), the precise 
relationship between these, as well as the underlying mechanisms of the rapid reduction in 
contractile function remains elusive. Previous studies suggested, that changes in intracellular 
pH, phosphate concentration [PJ and myocardial NAD/NADH ratio [23], the decrease in 
myocardial calcium transient and responsiveness [reviewed in 24], and perhaps activation of 
mitochondrial ATP-dependent potassium channels (KAtp) [25] may play a role. Recently, a 
number of intracellular mediators (e.g. heat shock proteins, oxidative derivates, nitric oxide 
and several cytokines, such as tumour necrosis factor-alpha {TNF-a}) are thought to 
contribute to myocardial hibernation, most probably through initiating cellular apoptosis 
[reviewed in 26 and 27]. However, a clear explanation is still not available.
A returning question in the literature whether chronic hibernation is a form of 
repetitive, cumulative stunning [11, 28, 29]. Some animal studies have shown, that repeated 
ischaemic insults may result in cumulative effects on contractility; the duration and the 
severity of repeated myocardial stunning greatly exceed those induced by a single ischaemic 
episode [30-33]. Many patients with coronary artery disease experience recurrent episodes of 
ischaemia within the same myocardial region. These may occur so frequently, that the 
myocardium remains reversibly depressed for a longer period. It is therefore possible that in 
certain clinical cases, contractile dysfunction is secondary to repetitive episodes of stunning, 
rather than results from „pure” hibernation [34]. However, there is some evidence, that the 
metabolic changes in repetitive stunning and hibernation are different [35]; i.e. opposite to 
stunning, the regional oxygen consumption in the hibernating myocardium is downregulated 
[36]. This also confirms different mechanisms, although there is more likely that these two 
phenomenons exist together in the ischaemic heart [34,37].
1.1.3. Ischaemic preconditioning
Ischaemic preconditioning was first described by Murry and his colleagues in 1986 
[38]. They showed in dogs that four, 5 min occlusion periods of the circumflex branch of the
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left coronary artery, rather than resulting in cumulative ischaemic damage, significantly 
reduced the extent of ischaemic necrosis of a subsequent 40 min coronary occlusion. 
Preconditioning protects the myocardium against ischaemic damage (i.e. decreases infarct 
size) [38-40], against ischaemia and reperfusion-induced severe ventricular arrhythmias [41- 
45] and enhances the postischaemic contractile recovery (reduces myocardial stunning) [46- 
48]. Preconditioning also improves metabolic conditions of the myocardium during ischaemia 
[49,50], decreases myocardial oxygen consumption [51] and protects the endothelium against 
ischaemia-induced endothelial injury [52]. The protective effects of preconditioning could be 
proved in all studied species, including humans [53]. Apart from the „classical” ischaemic 
preconditioning (i.e. repeated, short coronary occlusions; [38]), endogenous protection can be 
induced by rapid cardiac pacing [45, 54-58], partial occlusion of a coronary artery [59-62], 
cyclic flow variations [63], alterations in myocardial energy supply-demand balance [64], 
myocardial stretch [65], and local administration of several substances („pharmacological 
preconditioning”; [66, 67]), or as recently described, by physical exercise [68-70].
The protective effects of preconditioning appear in two distinct phases. The initial 
phase occurs immediately after the preconditioning stimulus. This protection is extremely 
pronounced, but unfortunately transient; it lasts only for minutes or at most 1 to 2 hours. After 
this the protection disappeares [9, 11, 12, 71]. The protection, however, reappeares 20-24 h 
later [72] and this phase is known as delayed or second window of protection. Previous results 
of our group demonstrated that this „second window” of protection against ventricular 
arrhythmias disappeares about 48 or 72 hours after the cardiac pacing (preconditioning) 
stimulus [45]. However, if the pacing stimulus is repeated 48 h after the initial 
preconditioning intervention, the antiarrhythmic protection can be prolonged for further 48 or 
72 hours (i.e. 5 days after the initial stimulus) [73].
The mechanism of this marked endogenous protective phenomenon is still not 
completely understood, but there is strong evidence that endogenous diffusible mediators, 
released during ischaemia and reperfusion (i.e. preconditioning), such as adenosine, 
bradykinin, nitric oxide (NO), some prostanoids, endothelin, cathecolamines, oxygen free 
radicals, and opioid peptides may play a role in both phases of the adaptive response [74]. 
These mediators, through activation of membrane and/or soluble intracellular receptors, (i) 
initiate rapid intracellular alterations and (ii) through activation of various intracellular 
signalling mechanisms or pathways, lead to indication of de novo synthesis of several 
cardioprotective proteins (such as inducible nitric oxide synthase (iNOS), heat shock proteins, 
and antioxidant enzymes), which contribute to the delayed phase of protection [75, 76]. The
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role of sarcolemmal, and more likely mitochondrial ATP-dependent potassium (Katp) 
channels, as end effectors in the adaptive process has been described [77,78].
1.2. Relationship between coronary blood flow and myocardial contractile function
As it was mentioned above, under coronary hypoperfusion, without previous 
ischaemic interventions, myocardial contractile function is decreased in proportion to the 
reduction in regional blood flow („perfusion-contraction matching”; [22]).
However, there are a number of situations when such a direct connection between 
coronary flow and contractile function disappeares. For example, in the stunned myocardium, 
following reperfusion of the ischaemic myocardium, coronary blood flow completely restores, 
while myocardial contractility remains depressed for a longer period (from hours to weeks) 
[10]. Similarly, a „perfusion-contraction mismatch” may occur after coronary 
microembolisation [79-82]. Infusion of microparticles into a main coronary artery results in a 
transient decrease in coronary and myocardial tissue blood flow, as well as in regional 
contractility whithin the supplied area, but these flow changes return to normal, while 
segmental contractile function remains decreased. NO and TNF-a seem to mediate this 
functional deterioration [82]. Coronary microembolisation is common in the clinical practice; 
e.g. during distal embolisation of an unstable plaque, or during angioplasty of an 
atherosclerotic or thrombotic coronary lesion [80].
There are further ischaemic conditions, when „perfusion-contraction mismatch” may 
develop. For example, Schroder et al. showed in anaesthetized dogs, that the decrease in 
regional myocardial contractility during two, consecutive episodes of partial occlusion 
resulting from the same grade of flow reduction was more marked, if a preconditioning 
stimulus (5 min total occlusion) had been performed between these partial occlusions [83,84]. 
Similarly, Minamino et al. [50] observed in dogs that (compared to the non-preconditioned 
controls), a single 5 min preconditioning stimulus resulted in a more marked depression in 
segmental contractile function and a less pronounced metabolic deterioration during a 
subsequent low-flow ischaemic episode. Recently, Marti et al. reported that in anaesthetized 
dogs, 5 days after a series of preconditioning stimuli (20 times 2 min of total coronary 
occlusions), the same grade of low-flow ischaema resulted in a more pronounced decrease in 
segmental shortening [85]. All of these studies indicate that following preconditioning the 
myocardium more easily adapts to the ischaemic conditions, which is manifested in a reduced
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myocardial contractile function and in a better preserved myocardial metabolism during the 
subsequent same grade of low-flow ischaemia.
1.3. Aims of the study
Re-occuring ischaemia is common feature in ischaemic heart disease. In patients with 
severe coronary artery disease, even the daily physical activity may result in recurrent 
ischaemia in the area supplied by a stenosed coronary artery [reviewed in 86]. Similarly, 
enhanced vasoreactivity of the culprit lesion in unstable angina may lead to frequent coronary 
spasms and repeated ischaemic episodes [87]. Nevertheless, if several ischaemic episodes 
occur within a short time, the first ischaemic event may act as a preconditioning stimulus and 
influences the consequences of the following ischaemic insults [88, 89]. At present, our 
knowledge is incomplete as regard changes in myocardial contractile function and metabolism 
during repeated ischaemic episodes. Further, we do not know whether preconditioning would 
modify regional myocardial contractile function during low-flow ischaemia 24 h later and 
what possible mechanisms are involved in this form of adaptation.
The main objective of the present thesis was to examine in open-chest, anaesthetized 
dogs, the changes in regional myocardial contractile function during repeated low-flow 
ischaemia and to determine whether preconditioning, induced by cardiac pacing or by 
physical exercise influences myocardial segmental contractility during these low-flow 
ischaemic episodes. To achieve this the followings have been analyzed:
(1) The mechanical and metabolic changes during repeated episodes of low-flow 
ischaemia and reperfusion;
(2) The effects of pacing-induced preconditioning on mechanical and metabolic 
conditions during these low-flow ischaemic cycles, commenced 24 h later;
(3) The effects of a single episode of physical exercise, induced 24 h previously, on 
segmental contractility during low-flow ischaemia;
(4) The possible role of nitric oxide in this cardiac adaptive phenomenon.
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2. MATERIALS AND METHODS
2.1. Experimental animals
Adult mongrel dogs of either sex, weighing in excess of 27 kg and allowed to access 
to food and water ad libitum a day before until starting the experiments, were used. The dogs 
were kept under quiet conditions at least one week before the commencement of the 
experiments and received humane treatment according to Hungarian and European laws, and 
to local institutional policy.
2.2. Pacing procedure
On the day of intervention dogs were lightly anaesthetized with an intravenous 
injection of sodium pentobarbitone (Phylaxia-Sanofi, Hungary) and allowed to breath 
spontaneously. A Cordat F4 bipolar pacing electrode was inserted, by way of the right jugular 
vein, into the right ventricle such as that it made contact with the ventricular endocardium. 
The correct position of the electrode was controlled by recording the endocardial 
electrocardiogram. Arterial blood pressure was monitored from the left carotid artery. Dogs 
were paced, at a rate of 220 beats min'1 for four 5 min periods, with 5 min resting intervals 
between the the pacing stimuli, as described previously [45]. In the sham-operated dogs the 
pacing electrode was introduced into the right ventricle but the dogs were not paced. The 
animals were then allowed to recover from the anaesthesia and kept separated under quiet 
conditions.
2.3. Physical exercise procedure
A separate group of dogs was allowed to adapt to laboratory conditions for a week. 
During this period the animals were transported to the laboratory and made to stand on the 
treadmill but were not exercised. After one week, dogs were subjected to a total exercise 
period of 21 min. The exercise protocol is shown in Figure 1. The slope and the speed of the 
treadmill were increased every 3 min reaching the maximum load during the final 3 min 
period. Heart rate (HR), measured from a chest lead surface electrocardiogram, was recorded
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during exercise. The sham-exercised dogs were only standing on the treadmill during the 
same period. After this procedure the animals were kept separated under quiet conditions.
13.5 %
13.5 %
12 %
8 %4 %4 %0 %
6.4 km/h , 7 km/h i 8 km/h , 8 km/h . 9 km/h • 10 km/h i 13 km/h
21189 12 156
Time (min)
Figure 1. Exercise protocol. Instrumented dogs were subjected to treadmill exercise for a period of 21 
min. Slope and speed of the treadmill were increased every 3 min, started from 6.4 km h'1 and 0 % 
grade. By the end of the exercise period the dogs ran on the treadmill with a speed of 13 km h"1 and a 
slope of 13.5 %.
2.4. Surgical interventions
The experimental model is illustrated in Figure 2. Twenty-four hours after the 
preconditioning (pacing or exercise) procedures, dogs were anaesthetized with sodium 
pentobarbitone (30 mg kg'1, i.v.). If necessary, additional doses of anaesthetic (100 pg kg"1 
min'1 i.v.) were infused during the experiment. The dogs were then intubated, and ventilated 
with room air (Harvard respirator, USA) at a rate and volume sufficient to maintain the 
physiological level of arterial blood gases and pH. Body temperature was monitored in the 
mid-oesophagus and maintained, by a heating pad, around 37 ± 0.5 °C. Polyethylene catheters 
were inserted into the right femoral artery for the measurement of blood pressure; into the left 
femoral artery to withdraw arterial blood samples; into the left ventricle, by way of the left 
carotid artery, for the measurement of left ventricular pressure and dP/dt; and into the right 
femoral vein for drug and anaesthetic administration. The pressure catheters were connected
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via transducers (P23XL Statham, Hugo Sachs, Germany) to the System-6 six channel 
haemodynamic apparatus (Triton Technologies, USA). These traces, together with a standard 
limb lead electrocardiogram, were recorded on an eight channel chart recorder (Medicor, 
Hungary) [90].
Thoracotomy was performed in the fifth intercostal space and the anterior descending 
branch of the left coronary artery (LAD) was prepared. Proximal to the first main diagonal 
branch a screw-type occluder was placed on the coronary artery. Just proximal to the occluder 
a Doppler flow-probe (diameter: 2 mm; Triton Technologies, USA) was positioned around the 
coronary artery to measure coronary blood flow (CBF) velocity (cm s'1). The severity of 
myocardial ischaemia was assessed from changes in the ST-segment, recorded from a hook- 
formed copper electrode fixed in the endocardium within the ischaemic area [90].
In some dogs, a small side branch of the LAD, near to the occlusion site, was prepared 
and catheterised. It was used either for the administration of N“-nitro-L-arginine-methyl- 
esther (L-NAME; Sigma) or of saline. In some of the dogs the local coronary vein adjacent to 
the LAD was cannulated and venous blood samples were taken for lactate determination.
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Figure 2. The experimental model in anaesthetized dogs for the measurements of haemodynamic 
parameters, coronary blood flow and segmental contractile function, as well as for the registration of 
changes in endocardial ST-segment elevation.
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2.5. Measurement of the regional myocardial contractile function
Regional myocardial contractile function was measured by ultrasonic technique as 
described by Theroux and colleagues [91]. In brief, two pairs of piezoelectric microcrystals 
were positioned in the endocardium both in areas supplied by the constricted LAD (ischaemic 
area) and the patent left circumflex (LCX; non-ischaemic area) coronary arteries. The emitter 
and receiver crystals, within each pair, were placed 8-12 mm apart and orientated along the 
main axis of contraction. From the contractile curve, end-diastolic segment length (EDL) was 
measured at the rapid initial upstroke of the left ventricular pressure curve, and the end- 
systolic segment length (ESL) was determined at the maximum of the negative left ventricular 
dP/dt curve. Local myocardial contractile function was expressed as percent changes in 
systolic segmental shortening (%SS) and described by the following equation:
%SS = (EDL - ESL) / EDL x 100 (%)
2.6. Assessment of myocardial tissue blood flow
In four paced and in four control dogs, changes in myocardial tissue blood flow were 
measured by means of the ’coloured microspheres’ method [92]. Ten million microspheres 
(15 pm), in one of four different colours, were injected through the left atrium immediately 
prior to the first episode of ischaemia (baseline) and also at 15 min during the first, third, and 
fourth occlusion periods (see chapter 2.10. Experimental protocols). Blood samples were 
collected from the thoracic aorta. At the end of the experiments the hearts were sectioned into 
vertical slices and endocardial and epicardial samples were taken from both the ischaemic 
(LAD) and the non-ischaemic (LCX) myocardial regions. Blood and tissue samples were then 
frozen for further processing. After digestion of the samples with potassium hydroxide, dye 
was extracted with dimethyl-formamide (DMF, Sigma) and the absorbance was measured via 
spectrophotometry (HP8453 UV-Vis Spectrophotometer, Hewlett-Packard, USA). Tissue 
blood flow, expressed in ml min'1 g"1 was calculated using a software developed in the 
Department of Pathophysiology, University of Essen, Germany [92].
2.7. Lactate determination
In four dogs of each of the paced and the sham-paced groups, blood samples were 
taken from the local coronary vein adjacent to the LAD and from the right femoral artery,
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immediately prior to ischaemia and then again at the end of each of the low-flow ischaemic 
episodes. The samples were centrifuged (3000 rpm) and the supernatants stored at -18 °C. 
Lactate extraction ratio (LER) was calculated according to the following equation:
LER = ([Lacfjart - [Lact]ven) / [Lact]art x 100 (%) 
where [Lact]art = arterial plasma lactate concentration and [Lact]ven = venous plasma lactate 
concentration.
2.8. Histological examination
At the end of the experiments, in four control and four previously paced dogs, 
transmural sections were made from the anterior (ischaemic) and from the posterior (non- 
ischaemic) regions of the ventricular wall. These tissue samples were fixed in 10 % 
formaldehyde and embedded in paraffin. Differences in tissue structure and glycogen content 
were examined with light microscopy after staining with haematoxylin and eosin, periodic 
acid Schiff (PAS) and PAS after amylase pretreatment.
2.9. Assessment of the area at risk
At the end of the experiment, the heart was stopped by an overdose of pentobarbitone 
and by intravenous injection of potassium chloride. The heart was removed and patent blue V 
dye was injected into the re-occluded LAD coronary artery (except in dogs, where myocardial 
samples were taken for the assessment of tissue blood flow or for histological examination). 
The delineated (risk) area was expressed as a percentage of the left ventricular wall together 
with the interventricular septum.
2.10. Experimental protocols
2.10.1. Protocol for the evaluation of changes induced by repeated ischaemia-reperfusion 
cycles, and modification of these changes by cardiac pacing. Assessment of the role of nitric 
oxide
This is illustrated in Figure 3. Four groups of dogs were used. The animals were
randomly assigned to control or paced groups. In the control group (group 1; n=16) dogs
s'*—underwent sham-operation and 24h later, after surgical intervention they were subjected to:
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four episodes of low-flow ischaemia. This was induced by the constriction of the LAD using 
the screw-type occluder, in order to produce an approximately 45-50% reduction in resting 
CBF. Each ischaemic episode was lasted for 20 min and followed by a 20 min reperfusion 
interval. Another group of dogs (group 2; n=15) underwent cardiac pacing, as described 
above, and 24 h later these dogs were also subjected to the similar four ischaemia/reperfusion 
insults. A further group of paced dogs (group 3; n=9) received N“-nitro-L-arginine-methyl- 
esther (L-NAME), a non-selective inhibitor of nitric oxide formation through nitric oxide 
synthase (NOS). This was infused into the small branch of the LAD, in a dose of 10 pg kg'1 
min'1, over a period of 10 min just prior to the first ischaemic insult. In previous studies, this 
dose of L-NAME attenuated the coronary vasodilator effects of the 20 ng kg'1 min'1 dose of 
bradykinin by 85% [93]. Non-paced, sham-operated dogs (group 4; n=10) were also given L- 
NAME by intracoronary infusion prior to the ischaemia.
In order to evaluate the effectiveness of NOS inhibition by L-NAME, a separated 
group of dogs (n=6) were given increasing doses of bradykinin (1, 2.5,5,10 and 25 ng kg'1), 
injected locally into a small side branch of the LAD prior to, immediately after, and again 40 
min after the intracoronary administration of L-NAME (10 pg kg'1 min"1, over 10 min). The 
vasodilator activity of bradykinin, which depends on the endothelial release of NO, was 
assessed by the measurement of changes in CBF. From the flow traces dose-response curves 
were plotted and EDso values were calculated.
2.10.2. Protocol for the evaluation of the effects of physical exercise on low-flow ischaemia- 
reperfusion-induced changes, 24 h later
This is illustrated in Figure 4. Two groups of dogs were used. In the exercised group 
(n=7) dogs underwent physical exercise, as described above, and 24h later they were 
subjected to two episodes of low-flow ischaemia. This was induced by the constriction of the 
LAD in order to produce an approximately 45-50% reduction in resting CBF. Each ischaemic 
episode lasted for 20 min and was followed by a 20 min reperfusion. Another group of dogs 
(n=9) served as controls, in this group dogs were standing on treadmill without exercise. 
Twenty-four hours later these animals were also subjected to the same ischaemia/reperfusion 
insults.
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Figure 3. Experimental protocol 1. On day one dogs underwent either right ventricular pacing or 
sham-operation. Twenty-four hours later the animals were subjected to four low-flow ischaemia / 
reperfusion interventions by partial occlusion of the LAD (50% reduction in CBF). Both control and 
paced dogs were given either saline (i.c. 0.5 ml min'1) or L-NAME (10 (xg kg'1 min'1) by intracoronary 
infusion, 10 min prior to the first ischaemic insult. Abbreviations: Occl. = partial occlusion; R = 
reperfusion; P = pacing (4x5 min, 220 beats min"1); L-NAME = NG-nitro-L-arginine methyl ester.
2.11. Statistical evaluation
All data are expressed as means ± s.e.m. and statistical analysis was performed by repeated 
measures two-way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test. A 
one-way ANOVA was undertaken to determine whether or not there were significant 
haemodynamic changes for drug treatment. Differences were considered significant if P<0.05.
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Figure 4. Experimental protocol 2. On day one dogs were exercised or stand on the treadmill and then 
24h later, were subjected to two episodes of low-flow ischaemia and reperfusion insult by partially 
occluding the LAD coronary artery (50% reduction in CBF).
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3. RESULTS
3.1. Effects of repeated low-flow ischaemia and reperfusion insults (control group)
3.1.1. Haemodynamic changes during repeated partial occlusions of the LAD
There were no significant differences in any of the haemodynamic parameters, 
measured either at baseline or during the repeated occlusion-reperfusion insults. The data for 
the four groups are given in Table 1. Partial occlusion of the LAD resulted in slight 
reductions in positive and negative LV dP/dtmax and a moderate increase in LVEDP. These 
alterations were rapidly returned to normal following reperfusion of the ischaemic 
myocardium.
R 3 04 R 4R 2 03Ol R 1 02Baseline
1. Control group
Heart rate (min'1) 
SABP (mmHg) 
DABP (mmHg) 
MABP (mmHg) 
LVSP (mmHg) 
LVEDP (mmHg) 
+dP/dtm„x (mmHg s'1) 
-dP/dtmax (mmHg s'1)
95±3 95±4 93±4100±3
119±3
80±3f
99+3 99±3 97±3 96±4101±3
122+3 113±3" 116±2117±2 113+3117+3 116±2 117±2
79±277+3 80±3 77±378±3 79±383±3 80±2
89±3 92±289±2 92±391±2 91±396±3 93±3 93±2
108±3" 107±3'110±2" 111±2
7.2±0.8
1988+92
2190±19l"
112±2
7.2±0.8
1996±110
2234+193
112±2
7.8±0.8
2011±100
2287±199
114±3
9.8±0.7'
2012±86
2146±166’
114±3
7.6±0.7
2097±104
2288±186
119±3
7.3±0.8
2109±110
2399+195
9.1±0.9
1834±79"
1978±184"
9.4±0.7
1808±80"
1987±195*
9.7±0.8
1914±80"
2088±190"
2. Paced group
Heart rate (min1) 
SABP (mmHg) 
DABP (mmHg) 
MABP (mmHg) 
LVSP (mmHg) 
LVEDP (mmHg) 
+dP/dtm„ (mmHg s'1) 
-dP/dW (mmHg s'1)
104 ±4 
115±2
102+4
111±3
102±4
112±2
105+4
115+2
107±4
113±2
108±4
113+4
76±3’
88±3f
108±4
9.7±0.8'
1956±105’
2006±120"
108±5
115±3
76±2f
89+2f
110±3
7.7±0.7
2089+102
2202±124"
108±4 
115±3
107±5
116*3*
77±2*
90±2*
111±3’
7.0±0.6
2154±119
2319±134
78±3 75±3 77±377±2 78±3 77±3
89±3 90±2 87±3 89±36
108±3
7.5±0.9
2073±92
2072±105‘
90±2 91±2
111±2
7.7±0.9
2122±103
2174±111
108±2 
10.0±0.9' 
1941±96 
1965*108"
110±2
7.5±0.9
2156±104
2124±107
106±2
9.5±1.0
1884*83"
1861*106"
109±3
10.2±1.0*
1934+89"
2031±120‘
3. Paced + L-NAME 
Heart rate (min1) 
SABP (mmHg) 
DABP (mmHg) 
MABP (mmHg) 
LVSP (mmHg) 
LVEDP (mmHg) 
+dP/dtm„ (mmHg s'1) 
-dP/dw (mmHg s'1)
101+7
109±4
105±5
114±3
103±6
117±3
101+6
112±3
100±7
114±3
99±7 99±7 100±8
112±4
104±6
117±1 109±3 112±3
73±3 73+3 75+4 71±3 73±3 72±3 74±477+3 77+3
91±2 87±3 91±3 86±3 88±4 84±3 86±3 84±3 87±4
112+2
8.1±1.2
1916±94
2345+226
109±2
11.9*1.4"
1733±99
2119±224
112±3
9.2±1.2
1902±92
2275±220
107±2
11.4+1.3"
1771±100
2095±237
109+3 
9.2±1.3 
1911±95 
2256±241
104+3
12.2±1.4"
1736±112
2063±240
106±4
8.3±1.4
1909±113
2204±251
104±3
11.4±1.5"
1716+112
2013*228"
107±4 
8.9+1.1 
1921±112 
2171±233
4. Control+L-NAME
Heart rate (min') 
SABP (mmHg) 
DABP (mmHg) 
MABP (mmHg) 
LVSP (mmHg) 
LVEDP (mmHg) 
+dP/dtmax (mmHg s'1) 
-dP/dtm3x (mmHg s'1)
88*3"
114*3"
87±3"
114*3"
98+4 98±4 97±4 94±4 93±4 90±4 88±4
116±4‘ 117*4" 113±4" 116±3"129±4 125 ±4 123 ±4
95±5 95±5 92±5 88±5 88±4 85±4 85+486±4 86±4
98±5"
112±4"
94+4"
108*4"
95±3‘
110±3"
106±4
123+3
8.3±0.9
1831+140
2166±225
105±4
119±4
11.0+1.5"
1719±129
1946±193
102+4
118±4
8.3±1.6
1712±124
2078±225
98±4 
113±4 
7.8±1.3 10.0±1.2
1620±114" 1502±92"
1895±175" 1619*133"
95±4 96±3
109*3" 111±3
8.3±0.8
1616±108
1780±195"
10.5±1.5
1504*101"*
1769*170"
8.3±0.8 10.0+1.0
1603±105* 1549±106" 
1823±190" 1651*159"
Table 1. Haemodynamic changes during repeated ischaemia!reperfusion insults. Data were measured 
at the end of each intervention (20 min occlusion and reperfusion) and given as means ± s.e.m. 
*P<0.05 vs. baseline; fP<0.05 vs. control. O = low-flow ischaemia; R = reperfusion; SABP, DABP, 
MABP = systolic, diastolic, mean arterial blood pressure; LVSP = left ventricular systolic pressure; 
LVEDP = left ventricular end-diastolic pressure.
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3.1.2. Changes in coronary blood flow and coronary vascular resistance following repeated 
ischaemia-reperfusion cycles
In all experiments we attempted to reduce coronary blood flow of the LAD to achieve 
an approximate 50% reduction of the baseline, resting blood flow. When the ischaemic 
myocardium was reperfused, a marked (post-occlusion) hyperaemia occurred, with an about 
three fold increase in CBF in controls. This hyperaemia was similar in magnitude following 
each of the four constriction periods. The results for partial occlusions 1 to 4 are given in 
Table 2.
Changes in coronary vascular resistance (CVR) mirrored the changes in flow; it raised 
significantly from the initial value during the first partial occlusion, then decreased again 
markedly under the baseline following reperfusion. Changes induced by the subsequent 
occlusion / reperfusion insults were similar to that of the first one (Table 2).
3.1.3. Effects of repeated occlusion-reperfusion cycles on regional myocardial contractile 
function
Table 3 summarises the changes in EDL, ESL and segmental shortening (%SS) during 
partial coronary artery occlusions and reperfusions within the ischaemic (LAD) region, 
whereas Figure 5 shows the time-course of relative changes in %SS during the four 
ischaemia/reperfusion cycles in the ischaemic and normal myocardial regions. (This is 
expressed as a percentage of values measured at baseline).
In control dogs, the first partial occlusion of the LAD (occlusion 1) resulted in an 
immediate, 58 ± 7 % reduction in %SS. This reduction was somewhat less pronounced (40 ± 
6 %) by the end of the 20 min ischaemic episode, indicating that the pre-existing collaterals 
were opened ant that this resulted in a slight improvement in contractility whithin the 
ischaemic area during the first ischaemic period. The following (2 to 4) ischaemic episodes 
resulted in a more pronounced reduction in %SS (59 ± 6, 68 ± 6 % and 70 ± 6%, respectively; 
P<0.05; Figure 5). When the myocardium was reperfused, a transient increase in contractile 
function (of between 10 and 30 %) occurred, which lasted for about 5 min; then %SS was 
returned near to the initial value. Post-ischaemic myocardial dysfunction (stunning), which 
was slight (less than 10 % reduction in %SS), developed only after the release of the second
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partial occlusion. Figure 5 also shows that a marked, although statistically not significant 
„compensatory increase” in segmental contractility (about 15%) occurred within the non- 
ischaemic (LCX) region when the LAD was repeatedly constricted.
4. Control + 
L-NAME
3. Paced + 
L-NAME
1. Control 2. Paced
Baseline
CBF (cm sec'1)
CVR (mmHg cm'1 sec) 
Occlusion 1 
CBF (cm sec'1) (20’)
CBF (% of Baseline)
CVR (mmHg cm'1 sec) 
Reperfusion 1 
CBF (cm sec"1) (peak) 
CVR (mmHg cm'1 sec) 
CBF(cm s"1) (pre-occl.) 
CVR (mmHg cm'1 sec) 
Occlusion 2 
CBF (cm s'1) (20’)
CBF (% of pre-occl.) 
CVR (mmHg cm'1 sec) 
Reperfusion 2 
CBF(cm s'1) (peak)
CVR (mmHg cm"1 sec) 
CBF (cm's1) (pre-occl.) 
CVR (mmHg cm'1 sec) 
Occlusion 3 
CBF (cm s'1) (20’)
CBF (% of pre-occl.) 
CVR (mmHg cm'1 sec) 
Reperfusion 3 
CBF (cm s'1) (peak)
CVR (mmHg cm'1 sec) 
CBF (cm s"1) (pre-occl.) 
CVR (mmHg cm"1 sec) 
Occlusion 4 
CBF (cm s'1) (20’)
CBF (% of pre-occl.) 
CVR (mmHg cm'1 sec) 
Reperfusion 4 
CBF (cm's1) (peak)
CVR (mmHg cm'1 sec) 
CBF (cm s'1) (20 min.) 
CVR (mmHg cm'1 sec)
37.4±3.6
2.30±0.31
32.8±2.7
2.63+0.24
36.9±2.6
2.28±0.23
38.5±2.1 
2.27±0.17
17.7±1.5*
54.0+2.8*
5.78±0.62*+
20.2±1.9*
54.0±2.6*
4.06±0.60*
20.1±1.5*
54.5±1.1*
4.11±0.40*
21.4+1.1*
55.6±0.8*
3.94±0.28*
73.8±9.4n
1.67±0.37*
32.8±3.1
3.07+0.36
136.7±17.9*
0.65±0.12*
36.7±2.8
2.21±0.20
119.3+13.9*
0.70±0.11*
38.0+3.7
2.26±0.32
118.0+14.2*
0.87+0.13*
37.0±2.6
2.36±0.20
20.6+2.1*
54.2+0.7*
3.98±0.57*
17.6±1.6*
53.7±0.6*
5.56±0.73*
20.0±1.3*
54.1±0.8*
4.20±0.35*
20.3±1.5*
55.3±0.8*
4.12+0.35*
102.4+14.2*
0.83+0.11*
39.7±3.3
2.19±0.32
79.5±10.6*+
1.46±0.32*
34.8±4.6
2.93±0.38
110.5±12.6*
0.92+0.16*
37.9±3.3
2.38+0.25
130.8±18.3*
0.68±0.1*
38.5±2.9
2.19+0.18
18.6±2.4*
53.4+0.6*
5.26+0.70*
20.6±1.8*
54.3±0.9*
4.26+0.44*
20.9+1.5*
54.3±1.0*
4.00+0.34*
20.4±1.9*
51.4±1.1*
3.90±0.58*
113.2+13.8*
0.85±0.11*
37.9±3.6
2.40±0.28
118.0±20.0*
0.56±0.04*
40.1±2.5
2.17±0.22
116.4+18.8*
0.74±0.11*
39.9±3.5
1.93±0.20
78.7±11.3*t
1.46±0.32*
37.2+5.7
2.80±0.42
20.9+1.8* 
55.1±0.7* 
4.23 ±0.48*
21.6±1.7*
53.9±1.0*
3.94±0.47*
21.4±1.7*
53.6±0.8*
3.60±0.42*
19.7±2.8*
53.0±1.0*
5.15±0.75*
117.0±17.2*
0.88±0.12*
38.1±3.4
2.38±0.25
123.1±22.6*
0.54±0.05*
37.2±4.0
2.12±0.24
115.1±14.6*
0.69±0.07*
41.1±3.5
1.94±0.23
83.2±11.4*+
1.32±0.27*
37.6±5.4
2.71±0.38
Table 2. Changes in coronary blood flow (CBF) and in coronary vascular resistance (CVR) during 
repeated partial occlusions and reperfusions of the left anterior descending coronary artery. Data are 
given as means ± s.e.m., and measured at baseline and at the 20 min of the occlusion (20’). Flow 
values were also determined immediately after the re-opening of the coronary artery (peak) and at the 
end of the 20 min of reperfusion (pre-occl.). *P<0.05 vs. baseline; fP<0.05 vs. control group.
24
3. Paced + L-NAME 4. Control + L-NAME2. Paced1. Control
Baseline
EDL (mm) 
ESL (mm)
10.12 ± 0.05° 
8.82 ± 0.15 
12.88 ± 1.21
9.99 ± 0.02 
8.62 ±0.12 
13.68 ± 1.11
10.01 ± 0.02 
8.73 ± 0.07 
12.74 ± 0.71
10.02 ± 0.01 
8.73 ± 0.09 
12.67 ±0.10%SS
Occlusion 1
EDL (mm) 
ESL (mm)
10.84 ± 0.17* 
10.39 ± 0.16* 
4.17 ±0.63°
10.60 ± 0.25* 
9.81 ± 0.30* 
7.67 ± 1.10
10.57 ±0.17 
9.70 ± 0.26 
8.27 ± 1.33*
10.67 ±0.13 
9.91 ± 0.18* 
7.21 ± 0.76*%SS
Reperfusion 1
EDL (mm) 
ESL (mm)
10.23 ±0.12 
8.95 ± 0.17 
12.58 ± 1.19
10.26 ± 0.05 
8.93 ± 0.13 
12.99 ± 1.12
10.29 ± 0.14 
9.04 ± 0.12 
12.12 ±0.71
10.21 ± 0.15 
8.99 ± 0.17 
11.98 ± 1.02%ss
Occlusion 2
EDL (mm) 
ESL (mm)
10.91 ± 0.21* 
10.46 ± 0.21* 
4.10 ±0.61
10.78 ± 0.23* 
10.23 ± 0.27* 
5.29 ± 0.97"
10.38 ±0.18 
9.56 ± 0.29 
8.09 ± 1.57
10.49 ± 0.12 
9.74 ± 0.17* 
7.19 ± 0.78*%SS
Reperfusion 2
EDL (mm) 
ESL (mm)
10.13 ±0.14 
8.91 ±0.17 
12.06 ± 1.24
10.12 ± 0.04 
8.80 ± 0.13 
13.05 ± 1.04
10.51 ± 0.20 
9.27 ± 0.18* 
11.77 ±0.75
10.23 ± 0.15 
9.04 ± 0.15 
11.64 ±1.0%ss
Occlusion 3
EDL (mm) 
ESL (mm)
10.89 ± 0.22* 
10.43 ± 0.23* 
4.23 ± 0.62
10.75 ± 0.22* 
10.33 ± 0.27* 
4.00 ± 0.80
10.20 ±0.19 
9.35 ± 0.27 
8.46 ± 1.47°
10.45 ± 0.12 
9.69 ± 0.19 
7.33 ± 1.02°*■o%SS
Reperfusion 3
EDL (mm) 
ESL (mm)
10.04 ±0.15 
8.78 ± 0.17 
12.50±1.22
10.10 ± 0.07 
8.80 ± 0.15 
12.91±1.23
10.30 ± 0.15 
9.10 ±0.16 
11.70±0.74
10.26 ± 0.14 
9.08 ±0.14 
11.51±0.95%SS
Occlusion 4
EDL (mm) 
ESL (mm)
10.75 ± 0.20* 
10.28 ± 0.21* 
4.34 ± 0.66
10.66 ± 0.25* 
10.28 ± 0.28* 
3.74 ± 0.75
10.48 ± 0.15 
9.70 ± 0.22 
7.49 ± 0.93°*
10.39 ± 0.21 
9.59 ± 0.32 
7.86 ± 1.66°■ o%SS
Reperfusion 4
EDL (mm) 
ESL (mm)
10.06 ± 0.14 
8.78 ±0.16 
12.72 ± 1.19
10.07 ± 0.09 
8.74 ± 0.14 
13.24 ± 1.20
10.20 ± 0.15 
9.00 ± 0.16 
11.79 ±0.89
10.24 ± 0.16 
9.01 ± 0.15 
11.92 ±0.68%ss
Table 3. Changes in myocardial end-systolic (ESL) and end-diastolic lengths (EDL), and in segmental 
shortening (%SS) within the ischaemic area during repeated partial occlusions and reperfusions of the 
LAD. Data are expressed as means ± s.e.m., measured at the end (20 min) of each occlusion and 
reperfusion cycle. *P < 0.05 vs. baseline; aP <0.05 vs. control group, *P < 0.05 vs. paced group; "P < 
0.05 vs occlusion 1; °P < 0.05 vs. occlusion 2.
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Figure 5. Changes in segmental shortening within the ischaemic area (supplied by the LAD; filled circles) and non-ischaemic area (supplied by the LCX; 
open circles) during four consecutive low-flow ischaemia and reperfusion insults in the control and 24 h previously paced dogs, without or with L-NAME 
pretreatment before ischaemia (baseline value = 100%). Values are means ± s.e.m. P < 0.05 vs. baseline; fP < 0.05 vs. 20 min; §P < 0.05 vs. 60 min.
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3.2. Influences of cardiac pacing and physical exercise commenced prior to the repeated 
low-flow ischaemia / reperfusion insults
3.2.1. Effects of cardiac pacing on heart rate and blood pressure
Right ventricular pacing at a rate of 220 beats min'1, which represents an 
approximately 81 ± 4 beats min'1 increase in HR from the resting value (P<0.05), resulted in 
immediate reductions in systolic arterial blood pressure (of around 49 ± 5 mmHg; P<0.05). 
There was also a slight, transient elevation in the ST-segment (mean of 2.5 ± 0.5 mV; 
PO.05), recorded from the pacing electrode immediately after cessation of pacing.
3.2.2. Effects of physical exercise on heart rate
Exercise resulted in marked increase in heart rate (from 122±4 to 192±15 beats min'1; 
PO.05) within 1 min of the commencement of exercise which was slightly further increased 
(to 216± 13 beats min'1 by the end of the exercise period) (Figure 6). After cessation of 
exercise, the heart rate returned to resting value within approximately 10 min.
Time (min)
Figure 6. Changes in heart rate during the 21 min period of exercise. Values are means ± s.e.m. 
*P<0.05 compared to baseline.
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3.2.3. Haemodynamic changes during repeated partial occlusions of the LAD in paced and 
exercised dogs
Similarly to the control group, repeated ischaemia / reperfusion cycles resulted in no 
significant differences in any of the haemodynamic parameters in the paced (Table 1) and in 
the exercised dogs (Table 4) 24 h later. There were only slight, not significant decreases in 
heart rate, arterial blood pressure, positive and negative dP/dtmax and an increase in LVEDP 
during these ischaemic periods.
-dP/dt LVEDP+dP/dtControl MABPHR ■U
7.2±1.4
9.2±0.9
7.5±1.1
9.4±1.1
8.1±1.0
1999±130
1813+110
1966±142
1698±102
1967Ü41
1996±144
1926±123
1995±147
18261116
19831144
961310515
10414
10314
10214
10H5
Base
9313O 1
9312R 1
911302
9U3R 2
-dP/dt LVEDP+dP/dtmaxExercised MABPHR
7.511.4
10.011.7
7.111.6
10.012.0
7.511.8
23741152
22321144
23191153
21841121
2380H53
22701152
2026178
21581130
1980198
22021118
10214
10114
9914
10014
10114
10916
10816
10416
10316
10216
Base
O 1
R 1
02
R 2
Table 4. Haemodynamic changes during repeated ischaemia / reperfusion insults in control and 
exercised dogs. Data were measured at the end of each intervention (20 min of occlusion and 
reperfusion) and given as means ± s.e.m. O = partial occlusion; R = reperfusion; HR = heart rate (beats 
min1); MABP = mean arterial blood pressure; dP/dt (Hgmm sec'1); LVEDP = left ventricular end- 
diastolic pressure.
3.2.4. Changes in coronary blood flow and coronary vascular resistance following repeated 
ischaemia-reperfusion cycles in paced and exercised dogs
The LAD coronary artery was constricted in order to achieve an approximately 50 % 
reduction in resting blood flow. When the artery was reopened, post-occlusion hyperaemia 
was somewhat more marked both in the paced (4 fold increase in CBF vs. 3 fold in controls; 
P<0.05) and in the exercised groups (about 3.2 fold increase in CBF vs. 2.8 fold in its own 
controls; ns) than in the control, non-paced and not exercised dogs. This hyperaemic reaction 
was similar during each of the reperfusion periods. The coronary flow and resistance results 
for the paced dogs are given in Table 2 and for the exercised group in Table 5. Compared to 
the controls, there were no marked differences between groups, and changes induced by the
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consecutive occlusions / reperfusions were similar to those that occurred during and after the 
first occlusion.
R 20 minR 1 minR 20 min Occl. 2R 1 minOccl.lBase
Control
CBF
CVR
Exercised
CBF
CVR
42.7±2.6 23.6+1.3* 120.3+23.6* 40.8±3.2 22.2+1.7* 115.7+21.3*
2.24+0.18 4.06±0.26* 0.78±0.12* 2.28±0.19 4.1±0.28* 0.78+0.16*
43.9+3.1 23.4±1.5* 142.1+21.2* 40.2+2.8 21.6±1.5* 140.0±18.6*
2.33±0.22 4.31±0.28* 0.73±0.14* 2.45±0.2 4.64±0.32* 0.72±0.18*
40.9+4.4
2.24±0.22
40.3±3.3
2.52+0.24
Table 5. Changes in coronary blood flow and coronary vascular resistance (CVR) during repeated 
partial occlusions and reperfusions of the LAD in exercised and in control dogs. Data are given as 
means ± s.e.m., and measured at the 20 min of the occlusion. Flow values were also determined 
immediately after the re-opening (1 min) of the LAD and at the end (20 min) of the reperfusion period. 
*P<0.05 vs. baseline. CBF = coronary blood flow (cm s"1), CVR = coronary vascular resistance 
(Hgmm cm'1 s). Occl. 1 and 2 = low-flow ischaemic periods; R = reperfusion.
3.2.5. Effects of repeated occlusion-reperfusion cycles on regional myocardial contractile 
function in paced and in exercised dogs
Opposite to controls, in dogs, subjected to cardiac pacing or physical exercise 24 h 
previously, the repeated ischaemia-reperfusion cycles resulted in immediate, maximal 
reduction in segmental shortening even during the first episode of ischaemia (Tables 3 and 6 
summarize the changes in EDL, ESL and %SS), and there were no further reductions in %SS 
during the subsequent ischaemic insults (Figures 5 and 7). Furthermore, in these dogs 
reperfusion induced a somewhat more marked post-ischaemic hypercontractility than in the 
controls. This „compensatory” increase in regional contractility of the non-ischaemic (LCX) 
region was somewhat more enhanced than in the controls.
Base O 1 R 1 02 R 2
Control
EDL 10.8±0.31*
10.08±0.36*
6.91+1.15*
10.87±0.28*
10.32±0.32*
5.17±1.02*°
10.00±0.00
8.83±0.07
11.72±0.95
10.34±0.18
9.2+0.17
11.04±1.0
10.27±0.16
9.14±0.15
11.03±1.09
ESL
%ss
Exercised
EDL
ESL
10.75±0.25*
10.24±0.33*
4.84+1.22*"
10.82+0.20*
10.34±0.26*
4.53±1.0*
10.00±0.00
8.86±0.13
11.38±1.29
10.53+0.18
9.41±0.24
10.7+1.26
10.57±0.15
9.42±0.22
10.92±1.25%SS
Table 6. Changes in myocardial end-systolic (ESL) and end-diastolic lengths (EDL), and in segmental 
shortening (%SS) within the ischaemic area during repeated partial occlusions and reperfusions of the 
LAD in exercised dogs. Data are given as means ± s.e.m., measured at the end of each occlusion (20 
min) and reperfusion cycle. *P < 0.05 vs. baseline; "P <0.05 vs. control group, °P<0.05 vs. O 1. O = 
low-flow ischaemia; R = reperfusion.
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Figure 7. Relative changes (in percent of the baseline values) in segmental shortening within the 
ischaemic area (supplied by the LAD; filled circles) and non-ischaemic area (supplied by the LCX; 
open circles) during two consecutive low-flow ischaemia and reperfusion insults in exercised and 
control dogs. Values are means ± s.e.m. *P<0.05 vs. baseline; +P<0.05 vs. 20 min; §P<0.05 vs. Control.
3.2.6. Changes in myocardial tissue blood flow during repeated occlusions and reperfusions
The results are summarised in Table 7. There were no significant differences between 
control and paced dogs as regard the reductions of tissue blood flow during repeated 
ischaemic episodes. The relationship between local myocardial blood perfusion and 
contractility under basal conditions and during repeated ischaemic interventions in the two 
groups is illustrated in Figure 8.
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Occlusion 4Occlusion 3Occlusion 1Baseline
Control group
Ischaemic area 
endocardial 
epicardial 
endo/epi ratio 
Non-ischaemic area 
endocardial 
epicardial 
endo/epi ratio
69.9+5.4
85.3±5.6
0.82±0.04
67.6+6.0
85.9±6.1
0.78±0.05
72.9+5.1
87.6±7.4
0.84±0.05
124.6±10.8 
123.4±11.9 
1.02±0.04
116.8±10.5
111.3±13.4
1.09±0.08
118.5+9.4 
110.9±13.2 
1.11 ±0.08
123.5+10.4
114.9+13.9
1.11±0.07
122.5±10.8
118.7+14.0
1.06±0.06
Paced group
Ischaemic area 
endocardial 
epicardial 
endo/epi ratio 
Non-ischaemic area 
endocardial 
epicardial 
endo/epi ratio
53.5+8.0
68.2±6.1
0.76+0.08
57.9±8.5
72.5+6.6
0.78±0.07
60.0±9.1
72.6±7.0
0.80±0.08
104.6±5.7
110.7±5.6
0.94±0.01
94.1±9.4
106.8+5.7
0.89±0.05
98.1+7.6
109.7±6.5
0.90±0.03
99.2±4.8
105.0±6.2
0.95±0.02
97.0±5.8
106.8±7.9
0.91±0.02
Table 7. The effects of successive partial occlusions of the left anterior descending coronary artery on 
myocardial tissue blood flow within the ischaemic and non-ischaemic area in control and in paced 
dogs (n = 4 for each group). Data are expressed in ml min'1100 g'1. Values are means ± s.e.m.
Control Paced
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Figure 8. Relationship between tissue blood flow and segmental contractility within the ischaemic 
area measured in four control and in four paced dogs. Pacing abolished the shift in perfusion- 
contraction matching seen in the control group during the first (O 1) and the last two episodes (O 3 
and 4) of low-flow ischaemia. Values are means ± s.e.m. Abbreviations: %SS = segmental shortening 
(%); TBF = tissue blood flow (ml min i 100 g"1); B = baseline; O = partial occlusion.
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3.2.7. Histological examinations
There were no detectable histological lesions in myocardial samples taken from 
control and paced dogs. In the ischaemic tissue samples there were focal depletions in 
glycogen-content of the myofibrils within the sharply delineated subendocardial region. Such 
ultrastuctural changes were not seen in the non-ischaemic areas. There were no marked 
differences in histology between the control and paced dogs.
3.3. The role of nitric oxide (NO) in functional changes induced by repeated low-flow 
ischaemic episodes
L-NAME, an inhibitor of nitric oxide synthases (eNOS and iNOS), was given in 
intracoronary infusion in control and in paced dogs, in order to evaluate the contribution of 
NO in contractility changes during ischaemia / reperfusion cycles. Figure 9. shows that the 10 
pg kg'1 min'1 dose of L-NAME markedly reduced the vasodilator response of bradykinin, 
indicating an effective inhibition of bradykinin-induced generation of NO by NOS. This was 
similar in control and in paced dogs.
Control + L-NAME Paced + L-NAME
12
g
aa 80
S 60m
1 40
U
.5
20
0 0
0 0 55 10 15 20 10 15 20 2525
Dose of bradykinin (ng kg1)Dose of bradykinin (ng kg1)
Figure 9. Changes in coronary blood flow following increasing doses of bradykinin (1, 2.5, 5, 
10, 25 ng kg'1) before (filled lozenges), and 1 min (open squares) and 40 min (filled triangles) 
after administration of L-NAME. Values are means ± s.e.m.
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3.3.1. Effects ofL-NAME on the haemodynamic, coronary blood flow and vascular resistance 
and on the local contractile parameters
Although systemic haemodynamic parameters were not significantly influenced by the 
intracoronary infusion of L-NAME, coronary vascular resistance increased in the controls 
(from 2.64 ± 0.24 to 3.12 ± 0.31 mmHg cm^s) and in the paced dogs (from 2.00 ± 0.27 to 
2.30 ± 0.31 mmHg cm_1s; P<0.05). These increases in resistance were returned to pre-infusion 
levels prior to the commencement of the first coronary artery occlusion (Table 2). Systolic 
segmental shortening decreased in both groups following administration of L-NAME (from 
13.5 ± 1.3% to 12.9 ± 1.2 % in the control group and from 14.2 ± 1.1% to 13.7 ± 1.1 % in 
the paced group (P<0.05).
3.3.2. Haemodynamic changes during repeated partial occlusions of the LAD in L-NAME- 
treated dogs
There were no significant differences between paced and control dogs in the 
haemodynamic parameters during repeated ischaemia / reperfusion cycles (Table 1).
3.3.3. Changes in coronary blood flow and coronary vascular resistance following repeated 
ischaemia-reperfusion cycles; effects ofL-NAME
These results are given in Table 2. In these I^NAME-treated groups, repeated 
constrictions of the LAD resulted in an approximately 50 % reductions in blood flow during 
each ischaemic period. There was however an interesting observation in the L-NAME-treated 
dogs during reperfusion; i.e. the post-occlusion hyperaemia in both the paced (about 3.2 fold 
increase in CBF vs. 4 fold in paced without L-NAME; P<0.05) and the control group (about 
2.2 fold increase in CBF vs. 3 fold in controls without L-NAME; P<0.05) was less marked 
than in the untreated control and paced dogs. This hyperaemic reaction was almost the same 
during the consecutive reperfusions.
Coronary vascular resistance (CVR) measured at baselinein the L-NAME-treated dogs 
were not significantly different from the not treated groups (Table 2). Increase in CVR during 
the first partial occlusion was more pronounced in control dogs given L-NAME (P<0.05 vs. 
controls), although not significantly different in the paced + L-NAME group compared to
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those dogs that were paced without L-NAME treatment. During reperfusion CVR returned 
near to the baseline values. Changes induced by partial occlusions two to four, and also by 
reperfusion, were similar to those that occurred during and after the first low-flow ischaemic 
episode.
3.3.4. The assessment of the involvement of nitric oxide in changes of local myocardial 
contractile function during repeated low-flow ischaemia / reperfusion cycles
The local administration of L-NAME prior to the repeated occlusion-reperfusion 
cycles markedly attenuated the changes in %SS both in paced and control dogs (Table 3, 
Figure 6). Pretreatment with L-NAME abolished the adaptive effects of cardiac pacing on 
segmental contractility. Similarly, in the presence of L-NAME, there were less marked and 
similar reductions in %SS within the ischaemic segment in the control dogs during the 
consecutive partial occlusions. Furthermore, the ’compensatory increase’ in contractility, that 
was apparent within the normal, non-ischaemic segment during repeated occlusions especially 
in the paced dogs, was much reduced following the administration of L-NAME, as was the 
hypercontractility that resulted from reperfusion of the ischaemic area (Figure 5.). Further, 
the mild postischaemic myocardial depression (stunning) which could be observed at the end 
of the reperfusion cycles, and which was maintained until the next ischaemic insult, was 
blunted in dogs treated with I^NAME.
3.3.5. Changes in lactate production during repetitive ischaemia / reperfusion cycles in 
control dogs, in paced dogs and after L-NAME administration
Under normal conditions there were no significant differences between the groups in 
lactate extraction ratios (LER; 13 ± 4 % in control dogs, 14 ± 7 % in paced dogs, 21 ± 2% in 
paced dogs given L-NAME and 17 ± 1 % in control dogs given L-NAME). The first episode 
of ischaemia resulted in similar changes in LER (lactate production) in both control and paced 
dogs (-33 ± 26 % and -32 ± 7 %; respectively). In contrast, during the subsequent three 
ischaemic cycles, LER was decreased only in the controls (-21 ± 15 %, -20 ±12% and -12 ± 
14 %; respectively); in the paced dogs it remained unchanged (-32 ± 7 %, -30 ± 13 % and -28 
±9%, respectively). Following administration of L-NAME, lactate production was markedly 
increased in both groups. Thus, in the paced dogs, LERs were -67 ± 18 %, -61 ± 13 %, -69 ±
34
25 % and -68 ± 18 %, respectively and in the controls these were -84 ±4%, -81 ± 10 %, -65 ± 
13 % and -67 ± 10 % during partial occlusions 1 to 4, respectively.
3.3.6. Assessment of the area at risk and the severity of ischaemia during repeated partial 
occlusions of the LAD
The severity of myocardial ischaemia was assessed by changes in the ST-segment as 
recorded from the endocardial electrode within the ischaemic area. Repeated ischaemic 
interventions resulted in slight (2 to 4 mV) increases, which was similar in magnitude during 
the repeated partial occlusions in all groups.
There were no significant differences in the area at risk between the groups. Thus, the 
risk (ischaemic) area was 32.9 ± 1.1 % in the controls, 31.4 ± 1.0 % in the paced, 34.2 ± 1.4 
% in the exercised group, and 31.3 ± 1.0 % in the sham-operated but not exercised control 
dogs. Similarly, the risk area was 35.4 ± 1.1 % in the paced + L-NAME and 33.1 ± 1.5 % in 
the control + L-NAME groups.
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4. DISCUSSION
4.1. New findings
I. We described in anaesthetized open chest dogs that repeated partial coronary occlusions 
result in progressively decreasing regional contractile function within the ischaemic area 
(until a definite grade), without any significant changes in the resting segmental contractility 
during reperfusion.
II. We showed for the first time that 24 h after cardiac pacing, decrease in segmental 
shortening is more enhanced already during the first episode of low-flow ischaemia / 
reperfusion cycles and no further decrease occur.
III. These adaptive changes in regional contractile function were abolished both in the early 
and late phases of preconditioning after the local administration of L-NAME, a non-selective 
inhibitor of NO synthesis, resulting in metabolic deterioration during ischaemia. This might 
indicate that the protective role of NO is an adaptive process.
IV. Finally, we demonstrated that, as with cardiac pacing, a single episode of physical 
exercise, 24 hours prior to ischaemia, results in immediate maximal reduction in segmental 
contractility that occur during the first ischaemic episode. This may represent a form of 
cardiac preconditioning of clinical importance, indicating that the myocardium rapidly adapts 
to flow changes by reducing its contractility and thereby its energy and oxygen (metabolic) 
demands.
4.2. Effects of preconditioning on segmental contractile function during repeated 
episodes of low-flow ischaemia
Our studies demonstrate that in anaesthetized dogs, repeated low-flow ischaemic 
episodes induce a progressive reduction in systolic contractile function of the ischaemic 
myocardial segment. The maximum reduction occurs during the third episode of ischaemia, 
and an additional (fourth) ischaemic insult results in no further decrease in contractility. 
Regional contractility always returned near to the basal value following reperfusion, 
indicating that no myocardial stunning developed in this model following the repeated
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ischaemic insults. We may conclude, that the myocardium is able to adapt to the repeated 
ischaemic stress by reducing its contractile function and thereby oxygen and metabolic 
demands. This is also reflected in reduced lactate production during ischaemia. This 
functional adaptation to ischaemic stress would enhance the possibility of cell viability during 
a subsequent ischaemic episode. In other words, the early ischaemic insults may serve as 
preconditioning stimuli for the heart in order to protect itself against the harmful 
consequences of the subsequent ischaemic events.
A similar adaptation was achieved when hearts had been subjected to cardiac pacing, 
24 hours prior to the ischaemic cycles. This may represent a form of „delayed” 
preconditioning [45, 57]. Under these conditions the maximum observed reduction in 
ischaemic segmental contractile function was already apparent during the first low-flow 
ischaemic episode, which was much more enhanced than in the non-preconditioned hearts, 
and no further reductions occurred during the subsequent ischaemic insults (Figure 5). 
Previously, cardiac pacing was already demonstrated to provide effective early and delayed 
protection against ischaemic and reperfiision arrhythmias [45, 54, 57] and ischaemic 
myocardial necrosis [58, 94]. In our model we used this method to induce delayed 
preconditioning, because it - opposite to repeated short complete coronary occlusions - did 
not result in significant myocardial stunning, as it was apparent in the control and paced 
groups.
Two further findings are also of interest. First, the postocclusion hyperaemic response 
was more enhanced in the previously paced group, and it was accompanied by a larger 
transient hypercontractility of the reperfused area within the first few minutes of reopening 
the coronary artery (Table 2, Figure 5). Both changes were markedly attenuated following 
the inhibition of NO production due to L-NAME administration. Second, the „compensatory” 
increase in contractility, measured within the non-ischaemic (LCX) segment during 
ischaemia, was somewhat more marked in the paced dogs than in the controls (Figure 5). 
This increase in the contractile function of the non-ischaemic area is supported by the increase 
in CBF that normally occurs in the LCX branch when the anterior descending coronary artery 
is occluded (’compenastory vasodilation’, [69]). Presumably, this increased segmental 
contractility within the normal myocardial region is responsible for the observation that only 
slight but staistically not significant changes occurred in the global myocardial contractile 
function (LV dP/dtmax) in each of the groups (Table 1), despite that the affected, ischaemic 
area of the left ventricular wall was substantial (more than 30% of the region supplied by the
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LAD coronary artery). In both groups this compensation was abolished following 
administration of LrNAME.
We propose that the reduction in segmental contractility following repeated episodes 
of ischaemia (and 24 h after cardiac pacing) is due to a more economical metabolism rather 
than to any cumulative mechanical or ultrastructural damages that might have been expected 
following ischaemia. Certainly, there was no evidence of structural alterations in the 
contractile apparatus in our histological studies. Furthermore, no significant changes occurred 
in the collateral blood flow during repeated occlusions. Myocardial tissue blood flow, 
measured by the ’coloured microspheres’ method, was similar at any level of contractile 
dysfunction in both groups. Indeed, the only indication that any coronary collaterals had 
opened, occurred in control dogs, when segmental contractility during the first partial 
occlusion was improved by the end of the ischaemic period (Figure 5). This was not observed 
either during subsequent occlusions in the controls or in the paced dogs. If collateral 
recruitment had played a role in this adaptive phenomenon then an improvement in 
contractility, rather than a depression would have been expected during consecutive ischaemic 
events. This is consistent with previous studies, showing no significant changes in collateral 
blood flow during repeated periods of ischaemia in animals [88] and in man [89]. Similarly, 
there were no significant changes in the endocardial/epicardial flow ratio during repeated 
partial occlusions or 24 h after cardiac pacing. Thus, the adaptation in contractile function is 
not due to an altered endocardial blood supply, which markedly influences the contractile 
force of the ischaemic segment. Our results support the previous findings of others [50].
4.3. The role of NO in the contractile adaptation during ischaemia
Végh and colleagues have shown previously that nitric oxide plays an important role 
in dogs against ischaemic and reperfusion ventricular arrhythmias both in the early [97] and 
the delayed [98-100] phases of preconditioning. We have also proposed an increased 
formation of NO during ischaemia following preconditioning, which may contribute to the 
protection. The evidence for this comes from the experiments in which LrNAME was 
administered to both control and paced dogs prior to the repeated ischaemic challenges; this 
abolished the marked reductions in segmental contractility in both groups. Furthermore, L- 
NAME attenuated the hyperaemic reactions and transient hypercontractility that occurred
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within the ischaemic region immediately after opening of the obstruction. Thus, we suppose 
that the early ischaemic insults as well as cardiac pacing, 24 hours previously (i.e. the delayed 
phase of preconditioning), may enhance NO production, which results in progressive or more 
enhanced reductions in contractility during the repeated ischaemic insults and contributes to 
the marked increase in blood flow following reperfusion (post-occlusion hyperaemia), also 
suggesting NO involvement in the coronary vascular responses following ischaemia. 
Furthermore, the marked elevation in lactate production following L-NAME administration 
suggests that inhibition of NO generation not only abolishes the adaptive reduction in 
contractility but also increases anaerobic metabolism in the ischaemic tissue. Similarly, in 
more studies NO was found to decrease the ischaemic challenge of the myocardium [101-103] 
and oxygen consumption [104], resulting in better metabolic conditions and decreased lactate 
production during ischaemia.
4.3.1. Possible mechanisms by which NO contributes to the adaptive changes in contractility
Ischaemia elevates the intracellular amount of NO through activating the Ca2+- 
sensitive nitric oxide synthase enzyme (cNOS; [105-110]. Furthermore, upregulated cNOS 
activity [111] and enhanced production of bradykinin during ischaemia was observed after 
preconditioning [112], which may further enhance NO release during a subsequent ischaemia 
[108]. Newly synthetized enzymes also contribute to the more pronounced NO production; 
elevation in the amount of the cNOS protein was described 30 min after a hypoxic challenge 
[110], presumably through the hypoxic regulation of mRNA transcription. Nuclear factor- 
kappa-B (NFkB) appears in the myocardium after preconditioning [113, 114], which may 
refer to de novo synthesis of the inducible form of NOS (iNOS) in the cardiomyocyte [115, 
116], contributing to the enhanced NO production during ischaemia in the preconditioned 
myocardial tissue.
Although the precise mechanism responsible for the reduced myocardial function 
during low-flow ischaemia remains unclear, a significant role for adenosine [50] and nitric 
oxide [106] has been proposed. Thus, in patients with effort angina, endogenous NO reduced 
myocardial contractile function and improved metabolic function of the heart [106]. The 
results of Hori’s group, who used complete coronary artery occlusion, confirmed that the 
increased generation of NO during ischaemia may contribute to the reduced contractile 
response [50,105,106,108]. Furthermore, Heusch and colleagues found in anaesthetized pigs
39
that endogenous NO contributes to hibernation by reducing myocardial oxygen consumption 
[117]. This would help to maintain regional myocardial contractile function during ischaemia.
The effects of NO on myocardial contractility are still under debate. There is evidence 
for both the negative or the positive inotropic effects of nitric oxide which is most probable 
concentration dependent [for a detailed review see 116]. It seems, that in smaller intracellular 
concentrations (<1 pM) NO enhances, whereas in larger amount decreases contractility. The 
elevated amount of endogenous NO during ischaemia (e.g. following preconditioning) [105, 
107, 108, 117, 119] initiates the intracellular production of cyclic GMP through activation of 
the soluble guanylate cyclase [120, 121], which in turn activates the protein kinase G [114], 
resulting in the desensitization of the myofilaments to calcium [122]. Further, cGMP was 
found to decrease calcium influx through the L-type calcium channels [123]. In addition, NO 
was observed to directly inhibit the L-type calcium channels. Recently, an isoform of 
neuronal NOS was described to be located on the sarcoplasmic reticulum, which also might 
modulate Ca2+ ion transport of the sarcoplasmic reticulum [124]. Méry et al. described an 
additional action of cGMP, which in higher concentrations activates the phosphodiesterase 2 
(PDE2), leading to a decrease in the concentration of cAMP and modifieing L-type calcium- 
current, which in turn further decreases the contractile response [125].
Nitric oxide, derived in part from endothelial cells [126, and reviewed in 127], 
influences myocardial metabolism during ischaemia by reducing myocardial oxygen 
consumption [126, 128, 129]. The most important target seems to be cytochrom c oxidase 
[109, 130, 131] which is blocked reversibly already at small NO-concentrations (10-100 nM), 
in particular if the intracellular oxygen suppply is largely decreased [132]. Other enzymes in 
mitochondrial respiration were also found to be inhibited after an exposure to NO, e.g. 
complex I, complex II and aconitase [126]. Others confirmed a decrease in oxygen 
consumption through the inhibition of the electron transport chain following NO exposure 
[101]. The effect of NO in reducing oxygen consumption seems to be a direct effect, 
independent of cGMP [126]. Recently, a mitochondrial Ca2+-sensitive isoform of NOS was 
described [133], which may also contribute to the regulation of oxygen consumption. The 
blockade of myocardial respiration leads to reduced production of ATP during ischaemia, 
which might be, in part, responsible for the contractile dysfunction [134]. Although neither 
oxygen consumption, nor glucose uptake were measured in our present sudy, lactate 
extraction data show that inhibition of NO formation increased anaerobic metabolism.
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In our studies, L-NAME administriation after cardiac pacing did not completely 
abolish the enhanced reduction in contractility during low-flow ischaemic episodes if it is 
compared to the not paced dogs. Presumably, NO is not the only mediator in the late phase of 
preconditioning which might mediate contractile adaptation during ischaemia. After 
preconditioning a significant increase in adenosine-release during low-flow ischaemia was 
described, which also contributes to the negatív inotropic effects [50,135]. Although, we did 
not examine the role of adenosine in our experiments, the involvement of other mechanisms, 
or mediators, than NO, in the adaptive changes can not be ruled out.
4.4. Effects of physical exercise, as a preconditioning stimulus on myocardial 
contractility during ischaemia
There is a good deal of experimental and clinical evidence that physical exercise, as a 
„beneficial” stress is cardioprotective [68, 69, 136-139, for a detailed review see 140]. 
However, there is less known about the potential mechanisms of this exercise-induced 
cardioprotective effect. The available data suggest, that there are no substantial differences 
between the basic mechanisms of the early and late phases of protection induced by various 
preconditioning stimuli (i.e. short coronary occlusions, cardiac pacing or physical exercise). 
There are, of course, important differences between the effects, by which the heart rate is 
elevated during cardiac pacing or physical exercise, there is, however, common that both 
following cardiac pacing and exercise, the cardiac pressure load and the oxygen demand of 
the myocardium increases and an imbalance in oxygen supply-demand occures, which results 
from transient hypoxia within the myocardium, mostly in the endocardial layer.
It is proposed, that during exercise, several endogenous mediators are released (e.g. 
NO, chatecholamines, opioid peptides, prostanoids, bradykinin, reactive oxygen species) 
which almost certainly contribute to the cardioprotective effects. There is a number of 
evidence that NO is released during physical activity both in animals [104, 141], and in man 
[119, 142] and induces preconditioning-like protection. For example, we have shown that a 
single episode of physical exercise resulted in a 3 fold increase in iNOS activity 24 h later 
[69], when a marked antiarrhythmic effect had been detected during ischaemia and 
reperfusion. This effect was sensitive to aminoguanidin, a selective inhibitor of iNOS.
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Already more than two hundred years ago, a relationship between the severity of 
anginal pains and the physical activity of patients was observed [143]. Similarly, physical 
exercise has been found to decrease the incidence of sudden cardiac death, and cumulative 
cardiac death [144,145], as well as to reduce the extent of ischaemic myocardial necrosis and 
to attenuate the complications of ischaemic heart disease [146]. Clinical studies revealed that 
physical exercise test in patients resulted in a better tolerance to ischaemia if a primary 
exercise was performed (24 or 48 h previously); i.e. more time was required to reach the same 
level of ischaemic changes (ECG signs and / or anginal pain), whereas the myocardial oxygen 
consumption significantly decreased [139, 147-149]. In other studies, in patients, who 
underwent physical exercise test 24 h before angioplasty, there were less severe changes in ST 
segment during subsequent PTCA [138, 150] and this adaptation was independent of the 
collateral network [138].
However, there are few, and conflicting data about the effects of repeated physical 
stress or other ischaemic challenges on the contractile function in patients with ischaemic 
heart disease. Some studies presume - mostly based on theoretical explanations - that 
myocardial contractile function might decrease during ischaemic interventions following 
preconditioning and this results in a better metabolic condition for the heart [151-153]. In 
contrast, other studies found an improved segmental contractile function within the ischaemic 
region following preconditioning or repetitive ischaemia [154, 155]. It is clear that further 
experimental and clinical studies are required to give correct answer for these questions.
4.5. Conclusions
Repeated partial occlusions of a main coronary artery result in a progressive reduction 
in contractility whithin the ischaemic myocardium. This decreased contractility might provide 
a better cell viability during the subsequent ischaemic episodes. In other words, the early 
ischaemic insults may serve as preconditioning stimuli. Similarly, cardiac pacing or physical 
exercise 24 h prior to such ischaemic challenges evoke this adaptive contractile response. We 
suggest that the reduction in segmental contractility protects the myocytes by reducing the 
proportion of oxygen expended in contractility, thus promoting myocyte viability. It is 
therefore a protective adaptation designed to reduce myocyte injury during ischaemia. Our 
results also suggest that this adaptation might be mediated by nitric oxide.
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A question could be raised whether this adaptation (decrease in regional contractile 
function within the ischaemic area) is beneficial for the heart or for the whole organism. In 
our experimental model the area of the left ventricular wall that affected by ischaemia was 
substantial (the region supplied by the LAD was more than 30%), however this did not 
materially influenced global left ventricular function (LV dP/dtmax) and haemodynamic status. 
This suggests the importance of the compensatory changes that occur in the normal (non- 
ischaemic) myocardial region of the left ventricle. We believe that a decrease in regional 
contractility during ischaemia following preconditioning is protective for the myocardium - at 
least if the ischaemia does not involve a very large amount of myocardium. Although we do 
not know whether the same adaptive process would perform, if substantially more myocytes 
or a previously damaged heart were affected by ischaemia.
If we are correct in our hypothesis that preconditioning enables myocardium to adapt 
in such a way that cellular viability is maintained during ischaemia, the question arises as to 
whether this has a clinical significance. We think, it does. Successive reductions in coronary 
blood flow commonly occur in patients with coronary artery disease and these do not 
necessarily result from complete brief coronary artery occlusions; as we have shown, partial 
occlusions also result in significant downstream reductions in flow. These would result in 
reductions in contractility in the area supplied by the partially occluded vessel. The 
myocardium responds in two ways. First, the initial ischaemia acts as a preconditioning 
stimulus to reduce the effects of subsequent ischaemic periods. Second, a stimulus, that 
results in delayed preconditioning (cardiac pacing or exercise), has aleady prepared the heart 
to withstand later brief ischaemic periods by immediately reducing contractility (and thus 
sparing oxygen consumption) in the affected segment, thus shifting oxygen availability 
towards maintaining cellular integrity and survival.
Of clinical importance, physical exercise may provide a form of preconditioning 
which is easy to perform. Further regular physical exercise would maintain the myocardium 
in permanently protected status.
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